Retrospective baseline biomarker analyses in a first-in-human Phase 1 trial of the PKMYT1 inhibitor lunresertib (RP-6306) in pts with advanced solid tumors harboring CCNE1 amplification and/or deleterious alterations in FBXW7 or PPP2R1A

被引：0
|
作者：
Aguado-Fraile, Elia
Sethuraman, Sunantha
Petrone, Adam
Bacque, Emeline
Schram, Alison
Lheureux, Stephanie
Lee, Elizabeth K.
Koehler, Maria
Silverman, Ian M.
Rimkunas, Victoria
Yap, Timothy A.
机构：
来源：
MOLECULAR CANCER THERAPEUTICS | 2023年 / 22卷 / 12期
关键词：
D O I：
10.1158/1535-7163.TARG-23-B169
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
B169
引用
收藏
页数：2
相关论文
共 25 条
  • [21] First-in-human phase 1 study of the PARP/tankyrase inhibitor 2X-121 (E7449) as monotherapy in patients with advanced solid tumors and validation of a novel drug response predictor (DRP) mRNA biomarker.
    Plummer, Elizabeth Ruth
    Dua, Divyanshu
    Cresti, Nicola
    Suder, Aneta
    Drew, Yvette
    Stephens, Peter
    Foegh, Marie
    Knudsen, Steen
    McGonigle, Sharon
    Ink, Barbara
    Sarker, Debashis
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [22] First-in-human phase 1/2a study of a potent and novel CDK2-selective inhibitor PF-07104091 in patients (pts) with advanced solid tumors, enriched for CDK4/6 inhibitor resistant HR+/HER2-breast cancer
    Yap, Timothy A.
    Elhaddad, Abdelaziz M.
    Grisham, Rachel N.
    Hamm, John Turner
    Marks, Douglas Kanter
    Shapiro, Geoffrey
    Le Corre, Christophe
    Li, Jerry
    Lin, Tun Tun
    Liu, Feng
    Malky, Lara
    Moreau, Allison R.
    Neumann, Heather
    Juric, Dejan
    Sharma, Manish
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [23] Design and rationale of a first-in-human (FIH) phase 1/1b study evaluating KIN-3248, a next-generation, irreversible (irrev), pan-FGFR inhibitor (FGFRi), in adult patients with solid tumors harboring FGFR2 and/or FGFR3 gene alterations (NCT05242822).
    Goyal, Lipika
    Perez, Cesar Augusto
    Kato, Shumei
    Sharma, Manish
    Garmezy, Benjamin
    Kobayashi, Ken
    Franovic, Aleksandra
    Tam, Betty
    Voong, Cynthia
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [24] First-in-human first-in-class phase 1/2a study of the next generation CDK4-selective inhibitor PF-07220060 in patients (pts) with advanced solid tumors, enriched for HR+HER2-mBC who progressed on prior CDK4/6 inhibitors and endocrine therapy
    Yap, Timothy A.
    Giordano, Antonio
    Hamilton, Erika P.
    LoRusso, Patricia
    Bowers, Michelle
    Basu, Cynthia
    Billotte, Stephane
    Delioukina, Maria
    Liu, Feng
    Yang, Jing
    Sharma, Manish
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [25] Safety and preliminary efficacy from the phase 1 portion of MasterKey-01: A First-in-human dose-escalation study to determine the recommended phase 2 dose (RP2D), pharmacokinetics (PK) and preliminary antitumor activity of BDTX-189, an inhibitor of allosteric ErbB mutations, in patients (pts) with advanced solid malignancies.
    Schram, Alison M.
    Ahnert, Jordi Rodon
    Patel, Manish R.
    Jauhari, Shekeab
    Sachdev, Jasgit C.
    Zhu, Viola Weijia
    LoRusso, Patricia
    Nguyen, Danny
    Le, Xiuning
    O'Connor, Matthew
    Waters, Nigel
    Cook, Carl
    Witt, Karsten
    Humphrey, Rachel W.
    Janne, Pasi A.
    Hamilton, Erika P.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
123